Matches in Wikidata for { <http://www.wikidata.org/entity/Q61921512> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q61921512 description "assaig clínic" @default.
- Q61921512 description "clinical trial" @default.
- Q61921512 description "clinical trial" @default.
- Q61921512 description "clinical trial" @default.
- Q61921512 description "clinical trial" @default.
- Q61921512 description "ensaio clínico" @default.
- Q61921512 description "ensayo clínico" @default.
- Q61921512 description "ensayu clínicu" @default.
- Q61921512 description "essai clinique" @default.
- Q61921512 description "klinisch onderzoek" @default.
- Q61921512 description "клінічне випробування" @default.
- Q61921512 description "临床试验" @default.
- Q61921512 name "Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia" @default.
- Q61921512 type Item @default.
- Q61921512 label "Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia" @default.
- Q61921512 prefLabel "Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia" @default.
- Q61921512 P1050 Q61921512-1B4DD7EC-05D3-43D5-969E-37B8E86331D7 @default.
- Q61921512 P1050 Q61921512-A2590AD4-D41D-4EAF-B628-47F1197B19AC @default.
- Q61921512 P1132 Q61921512-61B845DD-22E3-4785-9605-D8FF4EF24389 @default.
- Q61921512 P1476 Q61921512-93A39FF0-8438-414D-BA9C-9A0C7B2AD169 @default.
- Q61921512 P17 Q61921512-9DD76DF1-49EE-46DA-BB64-EFD27EF47774 @default.
- Q61921512 P2899 Q61921512-50B0A1C3-63E7-4FFA-B00D-4064E16FEC2C @default.
- Q61921512 P3098 Q61921512-4C151F04-7420-4C2C-ACED-FC8458A0C875 @default.
- Q61921512 P31 Q61921512-17B972C9-0186-407F-A72A-9759B9E289E2 @default.
- Q61921512 P4135 Q61921512-124F7833-5DCE-4D89-9984-87D8FA2DBEEB @default.
- Q61921512 P4844 Q61921512-9A74FF0A-545A-47B5-BF07-3131624FEDB3 @default.
- Q61921512 P580 Q61921512-A8413BB3-0D31-4C92-9415-419888AED511 @default.
- Q61921512 P582 Q61921512-F7DC0BFD-35CD-45D2-92CC-4FE2E4877E89 @default.
- Q61921512 P6099 Q61921512-ACFB1B16-0E08-4591-B11C-64768210BBD8 @default.
- Q61921512 P8005 Q61921512-090ADD39-9E48-4E2B-B60A-CD72D9150837 @default.
- Q61921512 P8005 Q61921512-E58777C0-4568-4FA0-9CE3-408AC9A5116A @default.
- Q61921512 P8363 Q61921512-D5C6825C-7E17-4186-AC59-ABFEAF12F754 @default.
- Q61921512 P921 Q61921512-AFB91AD1-BFA4-42D9-A8F5-304ADABF4B7A @default.
- Q61921512 P1050 Q179630 @default.
- Q61921512 P1050 Q29496 @default.
- Q61921512 P1132 "+26" @default.
- Q61921512 P1476 "A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML" @default.
- Q61921512 P17 Q30 @default.
- Q61921512 P2899 "+18" @default.
- Q61921512 P3098 "NCT00425477" @default.
- Q61921512 P31 Q30612 @default.
- Q61921512 P4135 "+120" @default.
- Q61921512 P4844 Q418192 @default.
- Q61921512 P580 "2006-11-01T00:00:00Z" @default.
- Q61921512 P582 "2016-09-30T00:00:00Z" @default.
- Q61921512 P6099 Q42824440 @default.
- Q61921512 P8005 Q76651189 @default.
- Q61921512 P8363 Q78089383 @default.
- Q61921512 P921 Q22 @default.